CN Patent

CN114728002A — 治疗肺动脉高血压的方法

Assigned to Actelion Pharmaceuticals Ltd · Expires 2022-07-08 · 4y expired

What this patent protects

本公开涉及降低患有肺动脉高血压(PAH)的患者的疾病进展风险的方法，该方法包括向有需要的患者施用内皮素受体拮抗剂(ERA)、5型磷酸二酯酶(PDE‑5)抑制剂和前列环素受体激动剂(IP受体激动剂)的初始三联组合疗法。

USPTO Abstract

本公开涉及降低患有肺动脉高血压(PAH)的患者的疾病进展风险的方法，该方法包括向有需要的患者施用内皮素受体拮抗剂(ERA)、5型磷酸二酯酶(PDE‑5)抑制剂和前列环素受体激动剂(IP受体激动剂)的初始三联组合疗法。

Drugs covered by this patent

Patent Metadata

Patent number
CN114728002A
Jurisdiction
CN
Classification
—
Expires
2022-07-08
Drug substance claim
No
Drug product claim
No
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.